PA
ANIP icon

Perceptive Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Perceptive Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-125,399
Closed -$5.87M – 140
2017
Q2 		$5.87M Sell
125,399
-129,490
-51% -$6.25M 0.3% 63
2017
Q1 		$12.6M Sell
254,889
-12,211
-5% -$686K 0.72% 37
2016
Q4 		$16.2M Buy
267,100
+255,539
+2,210% +$15.6M 1.15% 22
2016
Q3 		$767K Sell
11,561
-55,600
-83% -$3.48M 0.05% 102
2016
Q2 		$3.75M Sell
67,161
-46,899
-41% -$2.28M 0.26% 69
2016
Q1 		$3.84M Buy
114,060
+101,260
+791% +$3.43M 0.34% 67
2015
Q4 		$578K Sell
12,800
-6,456
-34% -$278K 0.04% 98
2015
Q3 		$761K Sell
19,256
-307,901
-94% -$17.5M 0.06% 103
2015
Q2 		$20.3M Buy
327,157
+19,373
+6% +$1.15M 1.22% 16
2015
Q1 		$19.3M Sell
307,784
-4,716
-2% -$287K 1.5% 19
2014
Q4 		$17.6M Buy
+312,500
New +$13.8M 1.48% 20
2014
Q2 		– Sell
-45,000
Closed -$1.41M – 122
2014
Q1 		$1.41M Buy
+45,000
New +$1.19M 0.15% 85

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Perceptive Advisors's ANIP Position: Q3 2017 in Review

Perceptive Advisors sold out of ANI Pharmaceuticals (ANIP) in Q3 2017, closing a stake of 125,399 shares — an estimated $5.87M sold.

Perceptive Advisors first reported a position in ANIP in Q1 2014 and held it in 12 quarters. The position peaked at $20.3M in Q2 2015. 146 funds tracked by Wall St. Rank hold ANIP as of Q3 2017.

  • Perceptive Advisors reported no remaining ANI Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Perceptive Advisors sold 125,399 ANI Pharmaceuticals shares in Q3 2017, an estimated $5.87M.
  • Perceptive Advisors first reported a position in ANI Pharmaceuticals in Q1 2014 and held it in 12 quarters.
  • Perceptive Advisors's ANI Pharmaceuticals position peaked at $20.3M in Q2 2015.
  • 146 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2017.

Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.